Q4 2024 Corvus Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Corvus Pharmaceuticals Inc (CRVS) reported a 39% objective response rate in their phase one trial of soquelitinib for relapsed T cell lymphoma, with a 26% complete response rate, surpassing standard chemotherapy rates.
- The company has a strong cash position with $52 million in cash, cash equivalents, and marketable securities as of December 30, 2024, providing a financial runway into the first quarter of 2026.
- Interim data from the Phase 1 trial of soquelitinib in atopic dermatitis showed significant responses, with 26% achieving IGA 0 or 1 and 37% achieving EASI 75, with no significant safety issues observed.
- Corvus Pharmaceuticals Inc (CRVS) is advancing a Phase 3 trial for soquelitinib in relapsed peripheral T cell lymphoma, with promising progression-free survival data from earlier trials.
- The company is exploring new indications for soquelitinib, including a Phase 2 trial for autoimmune lymphoproliferative syndrome (ALPS) and plans for a solid tumor trial in renal cell cancer.
- Corvus Pharmaceuticals Inc (CRVS) reported a net loss of $12.1 million for the fourth quarter of 2024, significantly higher than the $6.7 million loss in the same period of 2023.
- The company recorded a non-cash loss of $33.4 million from changes in the fair value of its warrant liability during the full year 2024.
- Research and development expenses increased to $19.4 million for the full year 2024, up from $16.5 million in 2023, primarily due to higher clinical trial costs.
- The net loss for the full year 2024 was $62.3 million, more than double the $27.0 million loss reported for 2023.
- There is uncertainty regarding the efficacy and competitive positioning of soquelitinib in the broader market, particularly in autoimmune diseases, as the company is still in early stages of clinical trials.
Good afternoon, everyone. Thank you for standing by and welcome to the Corvus Pharmaceuticals fourth-quarter and full-year 2024 business update and financial results conference call. (Operator Instructions)
It is now my pleasure to turn the call over to Mr. Zack Kubow of Real Chemistry. Thank you. Please go ahead, sir.
Thank you, operator, and good afternoon, everyone. Thanks for joining us for the Corvus Pharmaceuticals' fourth-quarter and full-year 2024 business update and financial results conference call.
On the call to discuss the results and business updates are Richard Miller, Chief Executive Officer; Leiv Lea, Chief Financial Officer; Jeff Arcara, Chief Business Officer; and Ben Jones, Senior Vice President of Regulatory and Pharmaceutical Sciences. The executive team will open the call with some prepared remarks followed by a question-and-answer period.
I would like to remind everyone that comments made by management today and answers to questions will include forward-looking
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
